Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 On March 19, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw its price target raised by Wells Fargo from $515 to $550. The firm's analyst kept an Overweight rating on the shares. Wells Fargo anticipates a threefold growth in the market for the generalized Myasthenia Gravis (gMG), reaching $20 billion globally by 2036. Analysts cite new drugs and mechanisms, such as CD20, BAFF/APRILs, and next-generation complement inhibitors, as significant drivers of growth. The firm identifies Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Amgen (AMGN), and Regeneron (REGN) as the key beneficiaries of this growth, while expressing a notable belief in an upside to current Wall Street estimates. In a separate event, on March 18, 2026, Maxim upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Buy and maintained a $575 price target. According to the firm, Povetacicept has the potential to be a blockbuste
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision [Yahoo! Finance]Yahoo! Finance
- Vertex Pharma wins FDA label expansion for cystic fibrosis therapies [Seeking Alpha]Seeking Alpha
- Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States [Yahoo! Finance]Yahoo! Finance
- Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United StatesBusiness Wire
- 2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/12/26 - Beat
VRTX
Sec Filings
- 4/1/26 - Form 144
- 3/31/26 - Form 4
- 3/31/26 - Form 8-K
- VRTX's page on the SEC website